Literature DB >> 24795473

Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment.

Allan R Tenorio1, Yu Zheng2, Ronald J Bosch2, Supriya Krishnan2, Benigno Rodriguez3, Peter W Hunt4, Jill Plants5, Arjun Seth3, Cara C Wilson6, Steven G Deeks4, Michael M Lederman3, Alan L Landay5.   

Abstract

BACKGROUND: Defining the association of non-AIDS-defining events with inflammation and immune activation among human immunodeficiency virus (HIV)-infected persons with antiretroviral therapy (ART)-associated virological suppression is critical to identifying interventions to decrease the occurrence of these events.
METHODS: We conducted a case-control study of HIV-infected subjects who had achieved virological suppression within 1 year after ART initiation. Cases were patients who experienced non-AIDS-defining events, defined as myocardial infarction, stroke, non-AIDS-defining cancer, non-AIDS-defining serious bacterial infection, or death. Controls were matched to cases on the basis of age, sex, pre-ART CD4(+) T-cell count, and ART regimen. Peripheral blood mononuclear cells and plasma specimens obtained at the visit before ART initiation (hereafter, baseline), the visit approximately 1 year after ART initiation (hereafter, year 1), and the visit immediately preceding the non-AIDS-defining event (hereafter, pre-event) were analyzed for activated CD4(+) and CD8(+) T cells, plasma interleukin 6 (IL-6) level, soluble tumor necrosis factor receptor I (sTNFR-I) level, sTNFR-II level, soluble CD14 level, kynurenine-to-tryptophan (KT) ratio, and D-dimer level. Conditional logistic regression analysis was used to study the association between biomarkers and outcomes, with adjustment for potential confounders.
RESULTS: Higher IL-6 level, sTNFR-I level, sTNFR-II level, KT ratio, and D-dimer level at year 1 were associated with the occurrence of a non-AIDS-defining event. Significant associations were also seen between non-AIDS-defining events and values of these biomarkers in specimens obtained at baseline and the pre-event time points. Effects remained significant after control for confounders. T-cell activation was not significantly related to outcomes.
CONCLUSIONS: Interventional trials to decrease the incidence of non-AIDS-defining events among HIV-infected persons with virological suppression should consider targeting the pathways represented by these soluble markers. Clinical Trials Registration. NCT00001137.
© The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  ART; HIV; Non-AIDS morbidity; immune activation; inflammation

Mesh:

Substances:

Year:  2014        PMID: 24795473      PMCID: PMC4192039          DOI: 10.1093/infdis/jiu254

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  43 in total

1.  HIV status, burden of comorbid disease, and biomarkers of inflammation, altered coagulation, and monocyte activation.

Authors:  Kaku A Armah; Kathleen McGinnis; Jason Baker; Cynthia Gibert; Adeel A Butt; Kendall J Bryant; Matthew Goetz; Russell Tracy; Krisann K Oursler; David Rimland; Kristina Crothers; Maria Rodriguez-Barradas; Steve Crystal; Adam Gordon; Kevin Kraemer; Sheldon Brown; Mariana Gerschenson; David A Leaf; Steven G Deeks; Charles Rinaldo; Lewis H Kuller; Amy Justice; Matthew Freiberg
Journal:  Clin Infect Dis       Date:  2012-04-24       Impact factor: 9.079

2.  Impact of CD8+ T-cell activation on CD4+ T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy.

Authors:  Peter W Hunt; Huyen L Cao; Conrad Muzoora; Isaac Ssewanyana; John Bennett; Nneka Emenyonu; Annet Kembabazi; Torsten B Neilands; David R Bangsberg; Steven G Deeks; Jeffrey N Martin
Journal:  AIDS       Date:  2011-11-13       Impact factor: 4.177

3.  Interleukin-6, C-reactive protein, and tumor necrosis factor-alpha as predictors of mortality in frail, community-living elderly individuals.

Authors:  Silvia Giovannini; Graziano Onder; Rosa Liperoti; Andrea Russo; Christy Carter; Ettore Capoluongo; Marco Pahor; Roberto Bernabei; Francesco Landi
Journal:  J Am Geriatr Soc       Date:  2011-08-24       Impact factor: 5.562

4.  Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients.

Authors:  Tricia H Burdo; Janet Lo; Suhny Abbara; Jeffrey Wei; Michelle E DeLelys; Fred Preffer; Eric S Rosenberg; Kenneth C Williams; Steven Grinspoon
Journal:  J Infect Dis       Date:  2011-10-15       Impact factor: 5.226

5.  HIV replication and immune status are independent predictors of the risk of myocardial infarction in HIV-infected individuals.

Authors:  Sylvie Lang; Murielle Mary-Krause; Anne Simon; Marialuisa Partisani; Jacques Gilquin; Laurent Cotte; Franck Boccara; Dominique Costagliola
Journal:  Clin Infect Dis       Date:  2012-05-18       Impact factor: 9.079

6.  HIV-1 is not a major driver of increased plasma IL-6 levels in chronic HIV-1 disease.

Authors:  Carey L Shive; Angélique Biancotto; Nicholas T Funderburg; Heather A Pilch-Cooper; Hernan Valdez; Leonid Margolis; Scott F Sieg; Grace A McComsey; Benigno Rodriguez; Michael M Lederman
Journal:  J Acquir Immune Defic Syndr       Date:  2012-10-01       Impact factor: 3.731

7.  Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death.

Authors:  David R Boulware; Katherine Huppler Hullsiek; Camille E Puronen; Adam Rupert; Jason V Baker; Martyn A French; Paul R Bohjanen; Richard M Novak; James D Neaton; Irini Sereti
Journal:  J Infect Dis       Date:  2011-06-01       Impact factor: 5.226

8.  Inflammation, coagulation and cardiovascular disease in HIV-infected individuals.

Authors:  Daniel A Duprez; Jacqueline Neuhaus; Lewis H Kuller; Russell Tracy; Waldo Belloso; Stephane De Wit; Fraser Drummond; H Clifford Lane; Bruno Ledergerber; Jens Lundgren; Daniel Nixon; Nicholas I Paton; Ronald J Prineas; James D Neaton
Journal:  PLoS One       Date:  2012-09-10       Impact factor: 3.240

9.  T cell subsets in HIV infected patients after successful combination antiretroviral therapy: impact on survival after 12 years.

Authors:  Frederikke Falkencrone Rönsholt; Sisse Rye Ostrowski; Terese Lea Katzenstein; Henrik Ullum; Jan Gerstoft
Journal:  PLoS One       Date:  2012-07-17       Impact factor: 3.240

10.  Decreased naive and increased memory CD4(+) T cells are associated with subclinical atherosclerosis: the multi-ethnic study of atherosclerosis.

Authors:  Nels C Olson; Margaret F Doyle; Nancy Swords Jenny; Sally A Huber; Bruce M Psaty; Richard A Kronmal; Russell P Tracy
Journal:  PLoS One       Date:  2013-08-23       Impact factor: 3.240

View more
  262 in total

1.  CD8 T-Cell Expansion and Inflammation Linked to CMV Coinfection in ART-treated HIV Infection.

Authors:  Michael L Freeman; Joseph C Mudd; Carey L Shive; Souheil-Antoine Younes; Soumya Panigrahi; Scott F Sieg; Sulggi A Lee; Peter W Hunt; Leonard H Calabrese; Sara Gianella; Benigno Rodriguez; Michael M Lederman
Journal:  Clin Infect Dis       Date:  2015-09-23       Impact factor: 9.079

2.  Changes in Markers of T-Cell Senescence and Exhaustion With Atazanavir-, Raltegravir-, and Darunavir-Based Initial Antiviral Therapy: ACTG 5260s.

Authors:  Theodoros Kelesidis; Carlee Moser; James H Stein; Todd T Brown; Thuy Tien T Tran; Heather J Ribaudo; Michael P Dube; Otto O Yang; Judith S Currier; Grace A McComsey
Journal:  J Infect Dis       Date:  2016-06-28       Impact factor: 5.226

3.  Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s.

Authors:  Theodoros Kelesidis; Thuy Tien T Tran; James H Stein; Todd T Brown; Carlee Moser; Heather J Ribaudo; Michael P Dube; Robert Murphy; Otto O Yang; Judith S Currier; Grace A McComsey
Journal:  Clin Infect Dis       Date:  2015-04-22       Impact factor: 9.079

4.  HIV-exposed-uninfected infants have increased inflammation and monocyte activation.

Authors:  Sahera Dirajlal-Fargo; Marisa M Mussi-Pinhata; Adriana Weinberg; Qilu Yu; Rachel Cohen; D Robert Harris; Emily Bowman; Janelle Gabriel; Manjusha Kulkarni; Nicholas Funderburg; Nahida Chakhtoura; Grace A McComsey
Journal:  AIDS       Date:  2019-04-01       Impact factor: 4.177

5.  Suboptimal Adherence to Combination Antiretroviral Therapy Is Associated With Higher Levels of Inflammation Despite HIV Suppression.

Authors:  Jose R Castillo-Mancilla; Todd T Brown; Kristine M Erlandson; Frank J Palella; Edward M Gardner; Bernard J C Macatangay; Elizabeth C Breen; Lisa P Jacobson; Peter L Anderson; Nikolas I Wada
Journal:  Clin Infect Dis       Date:  2016-09-22       Impact factor: 9.079

6.  CD4+/CD8+ ratio, age, and risk of serious noncommunicable diseases in HIV-infected adults on antiretroviral therapy.

Authors:  Jessica L Castilho; Bryan E Shepherd; John Koethe; Megan Turner; Sally Bebawy; James Logan; William B Rogers; Stephen Raffanti; Timothy R Sterling
Journal:  AIDS       Date:  2016-03-27       Impact factor: 4.177

7.  Gut Mucosal Barrier Dysfunction, Microbial Dysbiosis, and Their Role in HIV-1 Disease Progression.

Authors:  Joseph C Mudd; Jason M Brenchley
Journal:  J Infect Dis       Date:  2016-10-01       Impact factor: 5.226

Review 8.  Cytokines and T-Cell Homeostasis in HIV Infection.

Authors:  Michael L Freeman; Carey L Shive; Thao P Nguyen; Souheil-Antoine Younes; Soumya Panigrahi; Michael M Lederman
Journal:  J Infect Dis       Date:  2016-10-01       Impact factor: 5.226

9.  Effects of Well-Controlled HIV Infection on Complement Activation and Function.

Authors:  Alexandria E-B Rossheim; Tina D Cunningham; Pamela S Hair; Tushar Shah; Kenji M Cunnion; Stephanie B Troy
Journal:  J Acquir Immune Defic Syndr       Date:  2016-09-01       Impact factor: 3.731

10.  The interferon paradox: can inhibiting an antiviral mechanism advance an HIV cure?

Authors:  Steven G Deeks; Pamela M Odorizzi; Rafick-Pierre Sekaly
Journal:  J Clin Invest       Date:  2016-12-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.